期刊
JOURNAL OF ATTENTION DISORDERS
卷 15, 期 3, 页码 183-192出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/1087054710362217
关键词
ADHD; female; follow-up; adolescence
资金
- National Institute of Mental Health [R01MH050657]
- McNeil Pediatrics
- Ortho-McNeil Janssen Scientific Affairs
- Pfizer
- Shire Pharmaceuticals
- Eli Lilly
- National Institutes of Health
- Shire, Inc.
- Alza
- AstraZeneca
- Bristol Myers Squibb
- Eli Lilly and Co.
- Janssen Pharmaceuticals Inc.
- McNeil
- Merck
- Organon
- Otsuka
- Shire
- NICHD
- Abbott
- Celltech
- Cephalon
- Esai
- Forest
- Glaxo
- Gliatech
- NARSAD
- NIDA
- New River
- Novartis
- Noven
- Neurosearch
- Pharmacia
- Prechter Foundation
- Stanley Foundation
- Wyeth
Objective: The main aim of this study was to examine the age-dependent remission from ADHD in girls transitioning through childhood into adolescence and early adulthood. Method: We conducted a 5-year prospective follow-up study of 123 girls with ADHD and 106 non-ADHD control girls aged between 6 and 17 years at ascertainment. ADHD was considered persistent at follow-up if participants met full diagnostic criteria for DSM-IV ADHD or met residual criteria for DSM-IV ADHD with associated impairment (Global Age Forum [GAF] score < 60). Results: By age 16 years, ADHD was persistent in 71% (95% CI = 61-79%) of girls with ADHD. Participants with persistent ADHD at follow-up had more psychiatric comorbidity, behavior problems, and functional impairment than girls with ADHD in remission. Remitted ADHD, however, continued to be associated with functional impairment relative to non-ADHD controls. Persistence at 5 years was predicted by increased behavioral impairment at baseline. Conclusion: This 5-year follow-up suggests that many girls with ADHD experience persistent symptoms and/or functional impairment through late adolescence and into early adulthood. (J. of Att. Dis. 2011; 15(3) 183-192)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据